Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide, Axatilimab, and Retifanlimab in Metastatic TNBC
NCT06959537Phase 1Suspended
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide and axatilimab in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Started Aug 2025; status: suspended.
02
Drugs
cyclophosphamideaxatilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06959537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959537.